Advertisement

Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study

  • A. Colzi
  • F. d’Agostini
  • R. Kettler
  • E. Borroni
  • M. Da Prada
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

The effect of reversible inhibitors of the monoamine oxidase type A (MAO-A), moclobemide (Aurorix®) and Ro 41-1049 (20 mg/kg i.p. each), as well as of reversible inhibitors of the MAO type B (MAO-B), Ro 19-6327 (1 mg/kg i.p.), on the outflow of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) was studied in the rat by transstriatal microdialysis. Reversible MAO-A inhibitors markedly increased the output of DA and concomitantly decreased the output of DOPAC and HVA. These effects were absent with the highly selective MAO-B inhibitor Ro 19-6327.

Keywords

High Pressure Liquid Chromatography Reversible Inhibitor Dopamine Outflow Monoamine Oxidase Type Phase High Pressure Liquid Chromatography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Da Prada M, Kettler R, Cesura AM, Richards JG (1988a) Reversible, enzymeactivated monoamine oxidase inhibitors: new advances. Pharmacol Res Commun [Suppl] 4:21–33.Google Scholar
  2. Da Prada M, Kettler R, Zürcher G, Keller HH (1988b) Hemmer der MAO-B und COMT: Möglichkeiten ihrer Anwendung bei der Parkinson-Therapie aus heutiger Sicht. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, S 309-322.Google Scholar
  3. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400–413.PubMedGoogle Scholar
  4. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss P-C, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29:279–292.Google Scholar
  5. Di Chiara G (1990) In vivo brain dialysis of neurotransmitters. TIPS 11:116–121.Google Scholar
  6. Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265:80–81.PubMedCrossRefGoogle Scholar
  7. Imperato A, Di Chiara G (1984) Trans-striatal dialysis coupled to reverse phase high pressure liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4:966–977.PubMedGoogle Scholar
  8. Waldmeier PC, Maître L (1975) Lack of significance of MAO-B for the in vivo deamination of dopamine. Naunyn Schmiedebergs Arch Pharmacol 287:R2–R3.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • A. Colzi
    • 1
  • F. d’Agostini
    • 1
  • R. Kettler
    • 1
  • E. Borroni
    • 1
  • M. Da Prada
    • 1
  1. 1.F. Hoffmann-La Roche LtdPharmaceutical Research DepartmentBaselSwitzerland

Personalised recommendations